SAB Biotherapeutics to Showcase SAB-142 Data at Breakthrough T1D Congress
Event summary
- SAB Biotherapeutics will present Phase 1 data for SAB-142 at the inaugural Breakthrough T1D Clinical & Research Congress on October 9-11, 2026.
- Presentations include oral and ePoster sessions detailing safety, efficacy, and mechanism of action of SAB-142 in type 1 diabetes (T1D).
- SAB-142 is a potentially disease-modifying, redosable immunotherapy targeting autoimmune T1D.
- The company is collaborating with Breakthrough T1D to advance innovative approaches beyond insulin administration.
The big picture
SAB Biotherapeutics' participation in the inaugural Breakthrough T1D Congress underscores the growing focus on disease-modifying therapies for autoimmune conditions. The company's proprietary technology, leveraging transchromosomic cattle to produce human immunoglobulin G, positions it uniquely in the biopharmaceutical sector. The strategic collaboration with Breakthrough T1D highlights a shared commitment to advancing innovative treatments beyond traditional insulin administration.
What we're watching
- Clinical Efficacy
- How the Phase 1 data for SAB-142 will influence the perception of its potential as a disease-modifying therapy for T1D.
- Regulatory Pathway
- Whether the data presented will accelerate the regulatory approval process for SAB-142.
- Market Positioning
- The pace at which SAB Biotherapeutics can differentiate SAB-142 in a competitive landscape of T1D treatments.
Related topics